GlassScriptPhysician profile
Matthew James Ferry
NPI 1437787181
$11,182.99
in general payments reported to CMS, 2019-2025
27 companies · $5,856 in 2025
The $5,856 reported for 2025 was more than what 90% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $41.62 · 2022: $1,183 · 2023: $1,211 · 2024: $2,891 · 2025: $5,856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,510 · Education: $449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,509.64 |
| Education | $448.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,118.29 | 2022-2025 | |
| Janssen Biotech, INC. | $1,986.94 | 2024-2025 | Tremfya |
| Ucb, INC. | $950.32 | 2023-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $905.01 | 2022-2025 | Opzelura, Opzelura |
| Regeneron Healthcare Solutions, INC. | $683.90 | 2022-2025 | Dupixent |
| Amgen INC. | $537.54 | 2022-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $440.51 | 2022-2025 | Nemluvio |
| Lilly USA, LLC | $432.80 | 2024-2025 | Ebglyss, Taltz, Olumiant |
| Genzyme Corporation | $425.11 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $350.46 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $339.55 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $329.63 | 2024-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $303.57 | 2023-2024 | Cabtreo, Arazlo, Jublia |
| Organon LLC | $256.16 | 2025 | Vtama, Hadlima |
| Pfizer INC. | $188.55 | 2021-2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $168.42 | 2024-2025 | Zoryve |
| Almirall LLC | $155.03 | 2025 | Seysara, Klisyri |
| Epi Health, LLC | $97.34 | 2022 | |
| Janssen Scientific Affairs, LLC | $93.34 | 2024 | Tremfya |
| Biofrontera INC. | $88.57 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Dermavant Sciences, INC. | $81.20 | 2023-2024 | Vtama |
| Verrica Pharmaceuticals INC. | $76.84 | 2024-2025 | Ycanth |
| Helsinn Therapeutics (U.S.), INC. | $41.24 | 2022 | |
| Kyowa Kirin, INC. | $37.77 | 2024-2025 | Poteligeo |
| Mayne Pharma Commercial LLC | $33.87 | 2025 | |
| Strata Skin Sciences, INC. | $28.00 | 2025 | Xtrac |
| Journey Medical Corporation | $13.92 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Ferry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.